

**Supplementary Table 1: PCR primers for Exon 5 in *CCND3***

CCND3\_F CCTAACCTCCCCAGACTTCC  
CCND3\_R AGCTTGACTAGCCACCGAAA

**Supplementary Table 2: Sanger sequencing analysis of Exon 5 of CCND3 (NM\_001760) in cell line analysed in this study**

<b>Cell line</b>	<b>Amino acid change 1</b>	<b>Nucleotide change 2</b>
Gumbus	p.T283A	c.847A>G
BL41	p.S259fs	c.775_841delinsGCCCAGACCATCTCCAGC
BL67	p.R271fs	c.811_812insC
BL70	p.K268fs	c.801_802insC
SUDHL10	p.I290T	c.869T>C

positions according to NP\_001751

positions according to coding sequence of NM\_001760

**Supplementary Table 3: The frequency of mutations in D-type Cyclins from previous reports.**

Reference	Gene	BL	BCL-U	HGBL, DTH	HGBL, NOS	DLBCL		
						GCB	Un	ABC
Schmitz R, 2012, Nature	<i>CCND3</i>	14.6 (124)		ND		1.9 (158)	ND	10.7 (133)
Momose S, 2015, Leukemia	<i>CCND3</i>	25.8 (31)	33.3 (24)	29.2 (24)	22.2 (9)	15.9 (44)		ND
Reddy A, 2017, Cell	<i>CCND3</i>		ND			2.2 (315)	6.3 (128)	3.2 (310)
Rohde M, 2017, Haematologica	<i>CCND3</i>	35.4 (65 <sup>#</sup> )	14.3 (7)	NA	NA		15.4(13)	
Bouska A, 2017, Blood	<i>CCND3</i>	28.8 (52 <sup>*</sup> )					ND	
Karube K, 2017, Leukemia	<i>CCND3</i>		ND			1.3	0.7	3.3
Shipp MA, 2018, Nat Med	<i>CCND1</i>					0 (45)		0 (50)
	<i>CCND2</i>		ND			0 (45)	ND	0 (50)
	<i>CCND3</i>					4.4(45)		8 (50)
Schmitz R, 2018, NEJM	<i>CCND1</i>					0.6	0	0
	<i>CCND2</i>		ND			0.6	2.6	0.7
	<i>CCND3</i>					6.7	9.6	11.9
Ennishi D, 2019, JCO	<i>CCND3</i>		ND			12.1 (157)		ND

ND: not done or not analyzed (available), #: including leukemic BL, \*: denoted as molecular BL, abbreviations; BCL-U: B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL ‘former disease category in WHO 4th ed) “  
HGBL\_DTH: High-Grade B-Cell Lymphoma, with *MYC* and *BCL2* and/or *BCL6* translocation, HGBL\_NOS: High-Grade B-Cell Lymphoma, not otherwise specified , GCB: germinal center B-cell-like, ABC: activated B-cell-like, Un: unclassifiable. Parenthesis indicates the number of analyzed cases.